Suppr超能文献

一次抗阻训练并不能增强糖尿病前期和糖尿病个体的二甲双胍作用。

One Bout of Resistance Training Does Not Enhance Metformin Actions in Prediabetic and Diabetic Individuals.

机构信息

Exercise Physiology Lab at Toledo, University of Castilla-La Mancha, Toledo, SPAIN.

出版信息

Med Sci Sports Exerc. 2022 Jul 1;54(7):1043-1050. doi: 10.1249/MSS.0000000000002889. Epub 2022 Feb 10.

Abstract

PURPOSE

This study aimed to determine the separated and combined effects of metformin and resistance exercise on glycemic control, insulin sensitivity, and insulin-like growth factor 1 (IGF-1) in overweight/obese individuals with prediabetes and type 2 diabetes mellitus.

METHODS

Fourteen adults with a body mass index of 32.1 ± 4.1 kg·m-2, insulin resistance (HOMA-2 1.6 ± 0.6), and poor glycemic control (glycated hemoglobin, 6.9% ± 0.9%; 51.9 ± 10.7 mmol·mol-1) while taking metformin (1561 ± 470 g·d-1) were recruited. Participants underwent four 72-h long experimental trials in a randomized counterbalanced order, either 1) taking metformin (MET), 2) replacing metformin by placebo pills (PLAC), 3) taking placebo and undergoing a resistance training bout (RT + PLAC), and 4) taking metformin and undergoing the same RT bout (RT + MET). Interstitial fluid glucose concentration was frequently sampled to obtain 72-h glucose area under the curve (GAUC) and the percentage hyperglycemic glucose readings (>180 mg·dL-1; GPEAKS). Insulin sensitivity (i.e., HOMA-2) and IGF-1 were also assessed.

RESULTS

HOMA-2 was not affected by treatments. GAUC and GPEAKS were similarly reduced below PLAC during RT + MET and MET (all P < 0.05). In contrast, RT + PLAC did not affect glucose concentration. Metformin decreased serum IGF-1 concentrations (P = 0.006), and RT did not reverse this reduction.

CONCLUSIONS

A bout of full-body RT does not interfere or aid on metformin's blood glucose-lowering actions in individuals with prediabetes and type 2 diabetes mellitus.

摘要

目的

本研究旨在确定二甲双胍和抗阻运动对超重/肥胖的前驱糖尿病和 2 型糖尿病患者的血糖控制、胰岛素敏感性和胰岛素样生长因子 1(IGF-1)的单独和联合作用。

方法

共纳入 14 名体重指数(BMI)为 32.1±4.1kg·m-2、胰岛素抵抗(HOMA-2 为 1.6±0.6)和血糖控制不佳(糖化血红蛋白为 6.9%±0.9%;51.9±10.7mmol·mol-1)的成年人,他们正在服用二甲双胍(1561±470g·d-1)。参与者以随机交叉平衡的方式进行了 4 次 72 小时长的实验试验,分别为 1)服用二甲双胍(MET),2)用安慰剂药丸替代二甲双胍(PLAC),3)服用安慰剂并进行抗阻训练(RT+PLAC),和 4)服用二甲双胍并进行相同的 RT 训练(RT+MET)。频繁采集间质液葡萄糖浓度以获得 72 小时血糖曲线下面积(GAUC)和高血糖葡萄糖读数百分比(>180mg·dL-1;GPEAKS)。还评估了胰岛素敏感性(即 HOMA-2)和 IGF-1。

结果

治疗对 HOMA-2 没有影响。在 RT+MET 和 MET 期间,GAUC 和 GPEAKS 均明显低于 PLAC(均 P<0.05)。相比之下,RT+PLAC 对血糖浓度没有影响。二甲双胍降低了血清 IGF-1 浓度(P=0.006),而 RT 并没有逆转这种降低。

结论

一次全身抗阻训练不会干扰或辅助二甲双胍在前驱糖尿病和 2 型糖尿病患者中的降血糖作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验